Researchers from Weifang Medical University and affiliated organizations have published details on the discovery of novel hepatitis B virus (HBV) capsid assembly modulators (CAMs).
Researchers from Aligos Therapeutics Inc. presented preclinical data for ALG-001075, a novel capsid assembly modulator leading to the formation of empty capsids (CAM-E), being developed for the treatment of hepatitis B.
Researchers from Janssen Pharmaceutica NV have reported the discovery of novel hepatitis B virus (HBV) capsid assembly modulators (CAMs) as potential therapeutic candidates against HBV infection. Synthesis and optimization of a new series of di-fluoro azepane HBV CAMs resulted in the identification of compound [I] as the lead candidate with DNA EC50 value of 8.5 nM when assessed in the HepG2.2.15 cellular assay.
Promidis Srl has presented results from preclinical evaluations of potent capsid assembly modulators (CAMs) to prevent abnormal accumulation of empty capsids and associated T-cell-mediated liver injury.
Lessons learned from development of hepatitis C therapies could be applied to the underserved hepatitis B population, potentially leading to a functional cure through a combination of optimized drugs that attack the virus from different angles. That is the mission of 2-year-old Aligos Therapeutics Inc., a South San Francisco-based startup focused on liver-related diseases.